Literature DB >> 28624554

Outcomes of Urethroplasty to Treat Urethral Strictures Arising From Artificial Urinary Sphincter Erosions and Rates of Subsequent Device Replacement.

Sorena Keihani1, Jason C Chandrapal2, Andrew C Peterson2, Joshua A Broghammer3, Nathan Chertack4, Sean P Elliott5, Keith F Rourke6, Nejd F Alsikafi7, Jill C Buckley8, Benjamin N Breyer9, Thomas G Smith10, Bryan B Voelzke11, Lee C Zhao12, William O Brant13, Jeremy B Myers13.   

Abstract

OBJECTIVE: To evaluate the success of urethroplasty for urethral strictures arising after erosion of an artificial urinary sphincter (AUS) and rates of subsequent AUS replacement. PATIENTS AND METHODS: From 2009-2016, we identified patients from the Trauma and Urologic Reconstruction Network of Surgeons and several other centers. We included patients with urethral strictures arising from AUS erosion undergoing urethroplasty with or without subsequent AUS replacement. We retrospectively reviewed patient demographics, history, stricture characteristics, and outcomes. Variables in patients with and without complications after AUS replacement were compared using chi-square test, independent samples t test, and Mann-Whitney U test when appropriate.
RESULTS: Thirty-one men were identified with the inclusion criteria. Radical prostatectomy was the etiology of incontinence in 87% of the patients, and 29% had radiation therapy. Anastomotic (28) and buccal graft substitution (3) urethroplasty were performed. Follow-up cystoscopy was done in 28 patients (median 4.5 months, interquartile range [IQR]: 3-8) showing no urethral stricture recurrences. Median overall follow-up was 22.0 months (IQR: 15-38). In 27 men (87%), AUS was replaced at median of 6.0 months (IQR: 4-7) after urethroplasty. In 25 patients with >3 months of follow-up after AUS replacement, urethral complications requiring AUS revision or removal occurred in 9 patients (36%) and included subcuff atrophy (3) and erosion (6). Mean length of stricture was higher in patients who developed a complication after urethroplasty and AUS replacement (2.2 vs. 1.5 cm, P = .04).
CONCLUSION: In patients with urethral stricture after AUS erosion, urethroplasty is successful. However, AUS replacement after urethroplasty has a high erosion rate even in the short-term.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28624554     DOI: 10.1016/j.urology.2017.05.049

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Artificial Urinary Sphincter Complications: Risk Factors, Workup, and Clinical Approach.

Authors:  Roger K Khouri; Nicolas M Ortiz; Benjamin M Dropkin; Gregory A Joice; Adam S Baumgarten; Allen F Morey; Steven J Hudak
Journal:  Curr Urol Rep       Date:  2021-03-29       Impact factor: 3.092

2.  Comparison of 3.5 cm and transcorporal cuffs in high-risk artificial urinary sphincter populations.

Authors:  Michael T Davenport; Abdulhadi M Akhtar; Nabeel A Shakir; Adam S Baumgarten; Yooni A Yi; Rachel L Bergeson; Ellen E Ward; Allen F Morey
Journal:  Transl Androl Urol       Date:  2020-02

Review 3.  Management of urethral atrophy after implantation of artificial urinary sphincter: what are the weaknesses?

Authors:  Nathaniel H Heah; Ronny B W Tan
Journal:  Asian J Androl       Date:  2020 Jan-Feb       Impact factor: 3.285

4.  Urethral Stricture Formation Following Cuff Erosion of AMS Artificial Urinary Sphincter Devices: Implication for a Less Invasive Explantation Approach.

Authors:  Katharina Kuhlencord; Roland Dahlem; Malte W Vetterlein; Raisa S Abrams-Pompe; Valentin Maurer; Christian P Meyer; Silke Riechardt; Margit Fisch; Tim A Ludwig; Phillip Marks
Journal:  Front Surg       Date:  2022-02-09

5.  Presenting signs and symptoms of artificial urinary sphincter cuff erosion.

Authors:  Linley Diao; Samantha W Nealon; Gianpaolo P Carpinito; Shervin Badkhshan; Avery R Wolfe; Benjamin M Dropkin; Sarah C Sanders; Steven J Hudak; Allen F Morey
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.